Voyager Therapeutics Presents Robust, Multi-Species Results from Preclinical Studies of IV-Delivered, TRACER™-Generated Novel Capsids at the ASGCT 26th Annual Meeting

Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023

Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO